Phase 2 Studies

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

The purchase targets pacibekitug, an IL-6 antibody showing Phase 2 hs-CRP reductions linked to residual cardiovascular risk.